Electronic Acknowledgement Receipt				
EFS ID:	1121231			
Application Number:	10743697			
Confirmation Number:	5635			
Title of Invention:	Bispecific antibodies			
First Named Inventor:	Peter Kufer			
Correspondence Address:	Steven L. Highlander FULBRIGHT & JAWORSKI L.L.P. SUITE 2400 600 CONGRESS AVENUE AUSTIN TX 78701-3271 US 512-536-3184			
Filer:	Steven Lee Highlander/Christopher Jackson			
Filer Authorized By:	Steven Lee Highlander			
Attorney Docket Number:	DEBE:028US			
Receipt Date:	20-JUL-2006			
Filing Date:	22-DEC-2003			
Time Stamp:	15:45:55			
Application Type:	Utility			
International Application Number:				
Payment information:				

no

Submitted with Payment

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages	
1		DEBE028US_RESPONSE.p df	740393	yes	17	
	Multipart Description					
	Doc Desc Amendment - After Non-Final Rejection		Start	End		
			1	1		
	Claims		2	9		
	Applicant Arguments/Remarks	10	17			

Warnings:

Information:

Total Files Size (in bytes): 740393

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.